Targeted radiation attack tested for Tough-to-Treat prostate cancer
NCT ID NCT04876651
Summary
This study tested whether adding a new targeted radiation drug to standard care could better control advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug, 177Lu-DOTA-rosopatamab, is designed to seek out and deliver radiation directly to prostate cancer cells. The trial compared this combination against standard care alone in men whose cancer showed a specific marker (PSMA) on a scan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
'GenesisCare Murdoch'
Murdoch, Western Australia, 6150, Australia
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Austin Health
Melbourne, Victoria, 3083, Australia
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.